ReviewBritish journal of pharmacology2016
Inflammation in acute CNS injury: a focus on the role of substance P.
Review in British journal of pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 65 citations in OpenAlex.
- Blockade of the SP/NK1 receptor axis: multimodal neuroprotection via inflammatory suppression, hypoxic modulation, and lympho-vascular remodeling in global cerebral ischemia.Metabolic brain disease · 2026Article
- The role of substance P in Th17/Treg imbalance and ocular surface damage in chronic allergic conjunctivitis.Journal of translational medicine · 2025Article
- Exploring neurokinin-1 receptor antagonism for depression with structurally differentiated inhibitors.Experimental & molecular medicine · 2025Article
- Elucidation of the treatment mechanism of pulsed radiofrequency based on its antiinflammatory effects.Scientific reports · 2025Article
- NK1 tachykinin receptor antagonist treatment reduces cerebral edema and intracranial pressure in an ovine model of ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Article
- Effects of a neurokinin-1 receptor antagonist in the acute phase after thoracic spinal cord injury in a rat model.Frontiers in molecular neuroscience · 2023Article
- Article
- Enhancing Post-Stroke Rehabilitation and Preventing Exo-Focal Dopaminergic Degeneration in Rats-A Role for Substance P.International journal of molecular sciences · 2022Article
- A multi-staged neuropeptide response to traumatic brain injury.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2022Article
- The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review.International journal of molecular sciences · 2021Review
- Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?Physiological reports · 2021Review
- Article
- Neurokinin receptors and their implications in various autoimmune diseases.Current research in immunology · 2021Review
- The role of substance P in acupuncture signal transduction and effects.Brain, behavior, and immunity · 2021Article
- Involvement of hyaluronan in the adaptive changes of the rat small intestine neuromuscular function after ischemia/reperfusion injury.Scientific reports · 2020Article
- Regulation of BDNF-TrkB Signaling and Potential Therapeutic Strategies for Parkinson's Disease.Journal of clinical medicine · 2020Review
- Evaluating spatiotemporal microstructural alterations following diffuse traumatic brain injury.NeuroImage. Clinical · 2020Article
- Interferon-Gamma and Interleukin-1Beta Enhance the Secretion of Brain-Derived Neurotrophic Factor and Promotes the Survival of Cortical Neurons in Brain Injury.Neuroscience insights · 2020Article
- Substance P Improves Renal Ischemia Reperfusion Injury Through Modulating Immune Response.Frontiers in immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, a number of reports have shown that neurogenic inflammation may play a role in the secondary injury response following acute injury to the CNS, including traumatic brain injury (TBI) and stroke. In particular substance P (SP) release appears to be critically involved. Specifically, the expression of the neuropeptide SP is increased in acute CNS injury, with the magnitude of SP release being related to both the frequency and magnitude of the insult. SP release is associated with an increase in blood-brain barrier permeability and the development of vasogenic oedema as well as neuronal injury and worse functional outcome. Moreover, inhibiting the actions of SP through use of a NK1 receptor antagonist is highly beneficial in both focal and diffuse models of TBI, as well as in ischaemic stroke, with a therapeutic window of up to 12 h. We propose that NK1 receptor antagonists represent a novel therapeutic option for treatment of neurogenic inflammation following acute CNS injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.